Treatment of Androgenic Alopecia in Female Patients with Clinical or Biochemical Evidence of Hyperandrogenism
Female patients with androgenetic alopecia who also have clinical or biochemical evidence of hyperandrogenism represent a distinct clinical group. The presence of hyperandrogenism influences both the evaluation and the management approach for this form of hair loss.
Clinical Scenario
This protocol is specific to adult female patients with androgenetic alopecia (AGA) in whom clinical or biochemical evidence of hyperandrogenism is present — a finding that directly informs the management pathway.
Therapeutic Approach
Management in this population involves topical therapy applied to the scalp. The full protocol specifies the agent, the monitoring schedule, and the complete structured regimen — available via the link below.
Treatment Goals
The primary aims are to stop progressive hair loss and to induce hair regrowth with an increased hair count. Treatment response is assessed at 6 months.
References
DOI: 10.1111/jdv.14624
- Oral CPA can be considered to prevent progression of AGA in women with clinical or biochemical evidence of hyperandrogenism.
- Topical Minoxidil 2% solution 1 mL twice daily or half a cap of 5% minoxidil topical foam once daily is recommended to improve or to prevent progression of AGA in female patients above 18 years with AGA.
- As AGA is a naturally progressive disease, therapy can have two required outcomes, namely stop of hair loss and induction of hair regrowth.
- The response to treatment should be assessed at 6 months.
View source ↗